The efficacy of transdermal sumatriptan is too low for general use - A response

Headache

Volumn 54, Issue 1, 2014, Pages 172-174

  Goldstein, Jerome ^a   Smith, Timothy ^b   Pugach, Neil ^c   Griesser, James ^d   Sebree, Terri ^e   Pierce, Mark ^e  

^a San Francisco Clinical Research Center   (United States)

^b Sisters of Mercy Health System   (United States)

^c Private Practice   (United States)

^d Griesser Group   (United States)

^e NuPathe Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ANALGESIA; DRUG EFFICACY; DRUG USE; HUMAN; LETTER; MIGRAINE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; SUMATRIPTAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892179649     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12268     Document Type: Letter

References (13)

1. Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M,. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012; 52: 1402-1410.
2. Tfelt-Hansen PC,. The efficacy of transdermal sumatriptan is too low for general use. Headache. 2013; 53: 842-843.
3. Rapoport AM, Freitag F, Pearlman SH,. Low efficacy of transdermal sumatriptan in migraine [reply]. CNS Drugs. 2011; 25: 171-173.
4. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
5. Derry CJ, Derry S, Moore RA,. Sumatriptan (oral administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2) CD008615.
6. Roon KI, Lipton RB, Goadsby PJ, Ferrari MD,. Efficacy of six oral triptans at 1 h post-dose: A meta-analysis [abstract]. Cephalalgia. 2001; 21: 405. Abstract P2-K1.
7. Tfelt-Hansen P,. Parenteral vs. oral sumatriptan and naratriptan: Plasma levels and efficacy in migraine. A comment. J Headache Pain. 2007; 8: 273-276.
8. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T,. Zelrix: A novel transdermal formulation of sumatriptan. Headache. 2009; 49: 817-825.
9. Davies GM, Santanello NC, Lipton RB,. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000; 20: 554-560.
10. Lipton RB, Stewart WF,. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache. 1999; 39 (Suppl. 2): S20-S26.
11. Lipton RB, Cutrer FM, Goadsby PJ, et al. How treatment priorities influence triptan preferences in clinical practice: Perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin. 2005; 21: 413-424.
12. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S,. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine; defining the optimum doses of oral sumatriptan. Headache. 1998; 38: 184-190.
13. Zanchin G, Roncolato M, Fabbri L,. Sumatriptan (50 and 100 mg) in repeated migraine attacks: A patient preference study. J Headache Pain. 2000; 1: 33-38.